John W. Goethe, MD

Available data suggest that transcranial magnetic stimulation holds promise as a treatment for GAD. Here: a look at what we know.

Although most studies have focused on the risk of metabolic syndrome for patients with schizophrenia exposed to atypical antipsychotics, other psychiatric patients appear to be at risk for metabolic disturbances as well.7-9 Major depressive disorder (MDD) may be of particular interest because it is much more common than schizophrenia and is treated with a broad range of psychotropics.